Proceeds from the financing are set to go toward expanding its capacity and investing in technologies designed to complement and extend its proprietary antibody discovery engine, as well as toward expanding its staff and facilities . . .
- Drug Discovery
- Antibodies
- Antibody Drug Conjugates
- Bispecific Antibodies
- Epitope Mapping
- Financing
- GEN Edge
- Monoclonal Antibodies
AbCellera’s CEO: Flattening the Curve of Technology Development
Antibody Discovery Company Looking beyond COVID-19 with Eli Lilly; Expanding Technologies, Staff, and Facilities with $105M Series B Financing
An AbCellera scientist prepares reagents for a microfluidicsingle-cell assay. The company plans to expand its capacity, invest in technologies designed to complement and extend its proprietary antibody discovery engine, as well as expand its staff, and facilities through its just-completed $105 million in Series B financing. [AbCellera]
![Adcetris is indicated for Hodgkin lymphoma and systemic anaplastic large cell lymphoma. [© pressmaster - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug21_2011_7956603_ThumbsUp_SeattleGeneticsADCApproved1192082312-100x70.jpg "Seattle Genetics’ Antibody-Drug Conjugate Receives FDA Okay to Treat Lymphomas")